# VYVGART HYTRULO
> **BLA761304** · Biologics License Application · Sponsor: ARGENX BV · Approved 2023-06-20
## Drug
- **FDA Application Number:** BLA761304
- **Application type:** Biologics License Application
- **Brand name:** VYVGART HYTRULO
- **Generic name:** EFGARTIGIMOD ALFA AND HYALURONIDASE (HUMAN RECOMBINANT)
- **Active ingredients:** EFGARTIGIMOD ALFA AND HYALURONIDASE-QVFC
- **Dosage form:** INJECTABLE
- **Route:** INJECTION
- **Marketing status:** Prescription
- **Sponsor:** ARGENX BV
- **Manufacturer:** argenx US
- **First approval:** 2023-06-20
## Source
- [Drugs@FDA application overview](https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761304)
---
*MORVS · CC0 1.0*